YMI - In the cases where taxotere had been used as a prior treatment and not doxorubicin, if anything this would probably make the dox/tesmilifene treatment more effective as the cancer would not have had a chance to become resistant to the dox.
Also of note is that PFE was in a consultant or advisory role in the analysis of the tesmilifene data that was presented this year at ASCO.
Market Data 
Markets 
AI
